Denali Therapeutics Inc

28. Aug. 2026, 20:08 UTC

Denali Therapeutics shares are lower today, reflecting broader market trends amid rising U.S. Treasury yields and inflation concerns. The stock remains below its 20-day moving average.

25. Aug. 2026, 20:07 UTC

B. Riley analyst raised Denali Therapeutics Inc's price target to $30.00 while maintaining a Buy rating, coinciding with shares advancing since Monday's close.

24. Aug. 2026, 22:46 UTC

Denali Therapeutics Inc's shares are higher in after-market trading, reflecting a cumulative gain since Monday's close. No specific news was identified for this movement.

20. Aug. 2026, 19:16 UTC

Denali Therapeutics Inc shares are lower today, reflecting broader market trends. The stock has declined since Wednesday amid volatility in biotech and small-cap indices.

19. Aug. 2026, 20:02 UTC

DNLI is higher Wednesday, recovering with the SPDR S&P Biotech ETF.

17. Aug. 2026, 19:36 UTC

Denali Therapeutics Inc is trading higher today, supported by gains in the biotechnology sector. The stock remains near its 20-day moving average.

13. Aug. 2026, 19:36 UTC

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

12. Aug. 2026, 19:36 UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

11. Aug. 2026, 23:21 UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

10. Aug. 2026, 19:36 UTC

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

7. Aug. 2026, 19:26 UTC

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

6. Aug. 2026, 21:03 UTC

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

3. Aug. 2026, 19:46 UTC

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

31. Juli 2026, 20:02 UTC

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

30. Juli 2026, 19:18 UTC

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

29. Juli 2026, 22:01 UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

28. Juli 2026, 18:46 UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

27. Juli 2026, 19:56 UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

24. Juli 2026, 19:26 UTC

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

22. Juli 2026, 17:46 UTC

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

21. Juli 2026, 17:36 UTC

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

20. Juli 2026, 23:41 UTC

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.